Washington: Scientists have created a two-antibody cocktail that was able to cure monkeys infected with the deadly Ebola virus, revealed a new study.
The MIL77E cocktail was based on one of the most promising Ebola drugs, a three-antibody cocktail called ZMapp, which cured a number of foreign aid workers in West Africa during the latest and biggest Ebola outbreak, said the study published recently in the US journal Science Translational Medicine.
"The two monoclonal antibodies (mAb) in the MIL77E cocktail are 13C6 and 2G4, which act similarly to the three mAb ZMapp treatment," first author Xiangguo Qiu, a biologist at the Canadian Public Health Agency's National Microbiology Laboratory, told Xinhua.
One reason they used two antibodies, instead of three as in the ZMapp cocktail, is that one antibody named 4G7 from ZMapp "has been hard to produce and the yield is quite low compared to the other two mAbs," said Mr Qiu, who co-developed the treatment with Chinese researchers.
Another reason is "the cost of treatment would be decreased if it worked," she said.
ZMapp was produced by US-based Mapp Biopharmaceutical Inc, but two of its three components were originally developed at the National Microbiology Laboratory, and the third at the US Army Medical Research Institute of Infectious Diseases.
In the new study, Mr Qiu and colleagues produced 13C6 and 2G4 in modified Chinese hamster ovary cells and found that the two-antibody cocktail protected all three monkeys three days after infection with the Ebola virus.
However, a similar cocktail comprised of two ZMapp antibodies, which are produced in tobacco leaves instead of mammalian cells, protected only two of three monkeys.
"This finding is very exciting," Qiu said, given that ZMapp is only effective to Zaire Ebola, one of five species.
"It has the potential to include an additional monoclonal antibody against another Ebola virus strain, providing a broader coverage against outbreak strains," she said.
Currently, there are no licensed therapies against the Ebola virus.
The MIL77E cocktail was based on one of the most promising Ebola drugs, a three-antibody cocktail called ZMapp, which cured a number of foreign aid workers in West Africa during the latest and biggest Ebola outbreak, said the study published recently in the US journal Science Translational Medicine.
"The two monoclonal antibodies (mAb) in the MIL77E cocktail are 13C6 and 2G4, which act similarly to the three mAb ZMapp treatment," first author Xiangguo Qiu, a biologist at the Canadian Public Health Agency's National Microbiology Laboratory, told Xinhua.
Another reason is "the cost of treatment would be decreased if it worked," she said.
Advertisement
In the new study, Mr Qiu and colleagues produced 13C6 and 2G4 in modified Chinese hamster ovary cells and found that the two-antibody cocktail protected all three monkeys three days after infection with the Ebola virus.
Advertisement
"This finding is very exciting," Qiu said, given that ZMapp is only effective to Zaire Ebola, one of five species.
Advertisement
Currently, there are no licensed therapies against the Ebola virus.
COMMENTS
Advertisement
Chinese Scientists Create Mutant Ebola Virus In Lab That Causes Horrific Symptoms Ebola Virus: Origin, Transmission, And Impact 10 Years After Outbreak This Kenya Cave, Believed To Be Source Of Ebola, Could Cause Next Pandemic Vandalism At Kolkata Hospital Where Doctor Was Raped, Tear Gas Fired Starbucks' Indian-Origin CEO, Recently Fired, Never Worked Past 6 pm 150 mg Semen In Kolkata Doctor's Body, Suspect Gang-Rape: Parents To Court Delhi Airport Becomes 1st To Achieve Net Zero Carbon Emission Status US Welcomes India's Engagement In War Between Russia, Ukraine Google Says Iran Hackers Target Trump, Kamala Harris Campaigns Track Latest News Live on NDTV.com and get news updates from India and around the world.